Simplex Sciences sells single-stranded sequencesYale Daily News (blog)“The majority of people using our ladders are using them in sequencing and synthetic biology applications, but that is about as specific as we can be,” he said. “We can envision plen… Continue reading
Free Newsman: Market Research News By Market.BizImmunotherapy Drugs Market Forecasting CAGR of 13.2% with Industry Research of Organization Like Amgen …Digital JournalPune, India — (SBWIRE) — 02/26/2018 — The Immunotherapy Drugs Market accounted t… Continue reading
Irish TimesGene therapy making strides in treating rare diseasesIrish TimesThe idea behind gene therapy sounds simple – a person is born with a version of a gene that causes a disease, so you deliver a new gene to resolve the issue. But the path to get… Continue reading
Endpoints News |
Global syndicate backs Prokarium’s $10M round; Bavarian Nordic to test cancer vaccine with Imfinzi; AI startup buys …
Endpoints News The UK synthetic biology player Prokarium has raised $10 million from a global syndicate of investors to back its work on oral vaccines. The money came from the Riyadh Valley Company, the venture capital arm of King Saud University, as well as Sweden’s … |
The Scientist |
Human neural stem cell grafts to repair spinal cord injuries in monkeys
Science Daily Because the NPCs were derived from an 8-week-old human embryonic spinal cord, they possessed active growth programs that supported robust axon extension and appeared to be insensitive to inhibitors present in the adult CNS. Two weeks after the initial … Stem Cell Implants Improve Monkeys’ Grip After Spinal Cord InjuryThe Scientist Researchers use human neural stem cell grafts to repair spinal cord injuries in monkeysMedical Xpress |
Seeking Alpha |
This ‘Feel Good’ ETF Is A Top ETF Performer This Year
Seeking Alpha But this has also been a year of medical breakthroughs, landmark approvals, and M&A activity in the cancer immunotherapy segment. The Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) invests in this space, soaring more than 23% year to date and landing as … |